Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2013
This article has no abstract
Epistemonikos ID: 86403588905f0951c31aff93612a46b4b6bc10c3
First added on: Feb 05, 2025